Development and evaluation of a CRISPR-Cas13a system-based diagnostic for hepatitis E virus
Clinical Chemistry and Laboratory Medicine (CCLM) · 2024
DOI: 10.1515/cclm-2023-1007 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM), 2024. Verfasst von Manyu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control…. Hauptthemen laut MEDLINE: Hepatitis E virus, Hepatitis E, RNA, Viral, CRISPR-Cas Systems. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objectives
Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis worldwide. HEV RNA detection is the gold standard for HEV infection diagnosis and PCR methods are commonly used but are usually time-consuming and expensive, resulting in low detection efficiency and coverage, especially in low-income areas. Here, we developed a simpler and more accessible HEV RNA detection method based on CRISPR-Cas13a system.
Methods
A total of 265 samples of different types and sources, including 89 positive samples and 176 negative samples, were enrolled for evaluations. The sensitivity and specificity of the Cas13a-crRNA detection system were evaluated. The World Health Organization reference panel for HEV genotypes was used to evaluate the capability for detecting different HEV genotypes. The validity of the assay was compared with RT-qPCR.
Results
The 95 % limits of detection (LOD) of Cas13a-crRNA-based fluorescence assay and strip assay were 12.5 and 200 IU/mL, respectively. They did not show cross-reactivity with samples positive for hepatitis A virus, hepatitis B virus, hepatitis C virus, coxsackievirus A16, rotavirus, enterovirus 71, norovirus or enteropathic Escherichia coli . Different HEV genotypes (HEV1–4) can be detected by the assay. Compared to RT-qPCR, the positive predictive agreements of Cas13a-crRNA-based fluorescence and strip assay were 98.9 % (95 % CI: 93.9–99.8 %) and 91.0 % (95 % CI: 83.3–95.4 %), respectively. The negative predictive agreements were both 100 % (95 % CI: 97.8–100 %).
Conclusions
In conclusion, we established a rapid and convenient HEV RNA detection method with good sensitivity and specificity based on CRISPR-Cas13a system, providing a new option for HEV infection diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing, P.R. China.
- Department of Microbiology and Infection Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, P.R. China.
- Department of Clinical Laboratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China.
Zitieren
APA
Li, M., He, Q., Li, T., Wan, W., & Zhou, H. (2024). Development and evaluation of a CRISPR-Cas13a system-based diagnostic for hepatitis E virus. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2023-1007
Vancouver
Li M, He Q, Li T, Wan W, Zhou H. Development and evaluation of a CRISPR-Cas13a system-based diagnostic for hepatitis E virus. Clinical Chemistry and Laboratory Medicine (CCLM). 2024. doi:10.1515/cclm-2023-1007
BibTeX
@article{Li2024,
author = {Li, Manyu and He, Qiyu and Li, Tingting and Wan, Wenjun and Zhou, Haiwei},
title = {Development and evaluation of a CRISPR-Cas13a system-based diagnostic for hepatitis E virus},
journal = {Clinical Chemistry and Laboratory Medicine (CCLM)},
year = {2024},
doi = {10.1515/cclm-2023-1007}
}
EUVIMED